Choksi Laboratories [CHOKSILA] vs Dr. Lal PathLabs [LALPATHLAB] Detailed Stock Comparison
Choksi Laboratories
BSE
Loading...
Dr. Lal PathLabs
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Choksi Laboratories wins in 7 metrics, Dr. Lal PathLabs wins in 12 metrics, with 0 ties. Dr. Lal PathLabs appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Choksi Laboratories | Dr. Lal PathLabs | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 84.11 | 50.76 | Dr. Lal PathLabs |
| Price-to-Book Ratio | 5.32 | 12.00 | Choksi Laboratories |
| Debt-to-Equity Ratio | 123.52 | 7.14 | Dr. Lal PathLabs |
| PEG Ratio | -10.09 | 2.10 | Choksi Laboratories |
| EV/EBITDA | 13.47 | 36.90 | Choksi Laboratories |
| Profit Margin (TTM) | 3.52% | 20.29% | Dr. Lal PathLabs |
| Operating Margin (TTM) | 10.90% | 23.54% | Dr. Lal PathLabs |
| EBITDA Margin (TTM) | 10.90% | 23.54% | Dr. Lal PathLabs |
| Return on Equity | 6.45% | 22.08% | Dr. Lal PathLabs |
| Return on Assets (TTM) | 2.33% | 17.93% | Dr. Lal PathLabs |
| Free Cash Flow (TTM) | $40.91M | $5.15B | Dr. Lal PathLabs |
| Dividend Yield | N/A | 0.93% | N/A |
| 1-Year Return | 156.84% | -9.31% | Choksi Laboratories |
| Price-to-Sales Ratio (TTM) | 2.96 | 10.32 | Choksi Laboratories |
| Enterprise Value | $1.55B | $251.02B | Dr. Lal PathLabs |
| EV/Revenue Ratio | 3.66 | 9.92 | Choksi Laboratories |
| Gross Profit Margin (TTM) | 82.45% | 66.99% | Choksi Laboratories |
| Revenue per Share (TTM) | $61 | $303 | Dr. Lal PathLabs |
| Earnings per Share (Diluted) | $2.14 | $61.62 | Dr. Lal PathLabs |
| Beta (Stock Volatility) | 0.08 | 0.06 | Dr. Lal PathLabs |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Choksi Laboratories vs Dr. Lal PathLabs Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Choksi Laboratories | 4.25% | -8.02% | -20.17% | -3.34% | 56.24% | 95.99% |
| Dr. Lal PathLabs | -1.04% | 1.49% | -0.48% | 11.38% | 29.09% | 4.15% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Choksi Laboratories | 156.84% | 352.69% | 1,519.72% | 1,273.93% | 908.86% | 301.25% |
| Dr. Lal PathLabs | -9.31% | 33.74% | 53.87% | 254.85% | 254.85% | 254.85% |
News Based Sentiment: Choksi Laboratories vs Dr. Lal PathLabs
Choksi Laboratories
News based Sentiment: MIXED
September presented a mixed bag for Choksi Laboratories, with a share price decline following the AGM offsetting positive long-term returns and a commitment to shareholder communication. The reduced trading volume suggests growing investor caution, making it a moderately significant month for investors.
Dr. Lal PathLabs
News based Sentiment: NEGATIVE
The reported decline in both net profit and revenue during Q3FY24 is a significant negative development for Dr. Lal PathLabs. While the dividend payout offers some reassurance, the overall financial performance raises concerns about the company's short-term prospects and requires close monitoring by investors.
Performance & Financial Health Analysis: Choksi Laboratories vs Dr. Lal PathLabs
| Metric | CHOKSILA | LALPATHLAB |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.26B | ₹270.56B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 8,255 | 142,637 |
| 90 Day Avg. Volume | 7,354 | 134,697 |
| Last Close | ₹184.05 | ₹3,146.60 |
| 52 Week Range | ₹60.21 - ₹236.70 | ₹2,293.55 - ₹3,653.95 |
| % from 52W High | -22.24% | -13.88% |
| All-Time High | ₹236.70 (Aug 20, 2025) | ₹4,245.50 (Sep 13, 2021) |
| % from All-Time High | -22.24% | -25.88% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.05% | 0.11% |
| Quarterly Earnings Growth | -0.09% | 0.24% |
| Financial Health | ||
| Profit Margin (TTM) | 0.04% | 0.20% |
| Operating Margin (TTM) | 0.11% | 0.24% |
| Return on Equity (TTM) | 0.06% | 0.22% |
| Debt to Equity (MRQ) | 123.52 | 7.14 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹33.82 | ₹260.62 |
| Cash per Share (MRQ) | ₹0.88 | ₹139.63 |
| Operating Cash Flow (TTM) | ₹51.38M | ₹4.66B |
| Levered Free Cash Flow (TTM) | ₹15.23M | ₹4.87B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.93% |
| Last 12-Month Dividend | N/A | ₹30.00 |
Valuation & Enterprise Metrics Analysis: Choksi Laboratories vs Dr. Lal PathLabs
| Metric | CHOKSILA | LALPATHLAB |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 84.11 | 50.76 |
| Forward P/E | N/A | 106.46 |
| PEG Ratio | -10.09 | 2.10 |
| Price to Sales (TTM) | 2.96 | 10.32 |
| Price to Book (MRQ) | 5.32 | 12.00 |
| Market Capitalization | ||
| Market Capitalization | ₹1.26B | ₹270.56B |
| Enterprise Value | ₹1.55B | ₹251.02B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.66 | 9.92 |
| Enterprise to EBITDA | 13.47 | 36.90 |
| Risk & Other Metrics | ||
| Beta | 0.08 | 0.06 |
| Book Value per Share (MRQ) | ₹33.82 | ₹260.62 |
Financial Statements Comparison: Choksi Laboratories vs Dr. Lal PathLabs
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CHOKSILA | LALPATHLAB |
|---|---|---|
| Revenue/Sales | ₹112.42M | ₹6.70B |
| Cost of Goods Sold | ₹19.73M | ₹2.21B |
| Gross Profit | ₹92.69M | ₹4.49B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹12.28M | ₹1.58B |
| EBITDA | ₹29.04M | ₹2.20B |
| Pre-Tax Income | ₹6.27M | ₹1.81B |
| Income Tax | ₹2.42M | ₹471.00M |
| Net Income (Profit) | ₹3.85M | ₹1.34B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CHOKSILA | LALPATHLAB |
|---|---|---|
| Cash & Equivalents | ₹6.12M | ₹2.93B |
| Total Current Assets | ₹163.21M | ₹13.64B |
| Total Current Liabilities | ₹238.75M | ₹4.02B |
| Long-Term Debt | ₹159.63M | ₹1.03B |
| Total Shareholders Equity | ₹236.05M | ₹22.06B |
| Retained Earnings | ₹150.56M | ₹18.60B |
| Property, Plant & Equipment | ₹471.35M | ₹3.36B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CHOKSILA | LALPATHLAB |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | CHOKSILA | LALPATHLAB |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 8,255 | 142,637 |
| Average Daily Volume (90 Day) | 7,354 | 134,697 |
| Shares Outstanding | 6.97M | 83.37M |
| Float Shares | 3.47M | 37.19M |
| % Held by Insiders | 0.59% | 0.56% |
| % Held by Institutions | 0.00% | 0.33% |
Dividend Analysis & Yield Comparison: Choksi Laboratories vs Dr. Lal PathLabs
| Metric | CHOKSILA | LALPATHLAB |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹30.00 |
| Last 12-Month Dividend Yield | N/A | 0.93% |
| 3-Year Avg Annual Dividend | N/A | ₹20.00 |
| 3-Year Avg Dividend Yield | N/A | 0.28% |
| 3-Year Total Dividends | N/A | ₹60.00 |
| Ex-Dividend Date | N/A | Aug 06, 2025 |